Do Formulation Differences between the Reference Listed Drug and Generic Piperacillin-Tazobactam Impact Reconstitution?

Pharmaceutical differences between the reference listed drug (RLD) and generic formulations of piperacillin-tazobactam may impact the reconstitution process for intravenous administration. This study evaluated the RLD against three generic formulations and measured their reconstitution times using a standardized process. The mean (standard deviation [SD]) reconstitution time for one generic formulation was 5.57 (1.49) min, which was 35% to 42% longer (P < 0.002) than that for the RLD and two other formulations. Observable microscopic differences in powder particle morphology may explain these findings.     

β-catenin，c-myc和Cyclin D1在胰腺癌组织中的表达及意义

目的研究β-catenin异常表达、c-myc和Cyclin D1的高表达与胰腺癌发生、浸润、转移的关系。方法应用免疫组织化学方法检测5例正常胰腺组织和40例胰腺癌及13例相应癌旁组织中β-catenm、c-myc和Cyclin D1的表达。结果 5例正常胰腺组织及13例胰腺癌旁组织中β-catenin为正常表达,c-myc和Cyclin D1阴性表达,40例胰腺癌组织中25例有β-catenin的异常表达(25／40,62．5％),20例(20／40,50％)有c-myc的高表达,23例(23／40,57．5％)有Cyclin D1的高表达。β-catenin的异常表达率与淋巴结转移、浸润及病理分级相关(P<0.05),c-myc和Cyclin D1的高表达与分化程度,浸润,转移及病理分级无关,β-catenin的异常表达与c-myc的阳性表达不相关,而与Cyclin D1的阳性表达相关。结论β-catenin的异常表达可能主要是通过激活Cyclin D1引起细胞增殖,导致肿瘤的发生。     

Comparison of Carbon Supports in Anion Exchange Membrane Fuel Cells

Anion exchange membrane fuel cells (AEMFCs) are attractive alternatives to proton exchange membrane fuel cells due to their ability to employ nonprecious metals as catalysts, reducing the cost of AEMFC devices. This paper presents an experimental exploration of the carbon support material effects on AEMFC performance. The silver (Ag) nanoparticles supported on three types of carbon materials including acetylene carbon (AC), carbon black (CB), and multiwalled carbon nanotube (MWCNT)—Ag/AC, Ag/CB, and Ag/MWCNT, respectively—were prepared using the wet impregnation method. The silver loading in the catalysts was designed as 60 wt.% during the synthesizing process, which was examined using thermogravimetric analysis. The elemental composition of the prepared Ag/AC, Ag/CB, and Ag/MWCNT catalysts was confirmed using X-ray diffraction analysis. The nanoparticle size of Ag attached on carbon particles or carbon nanotubes, as observed by scanning electron microscopy (SEM), was around 50 nm. For the performance tests of a single AEMFC, the obtained results indicate that the maximum power density using Ag/MWCNT as the cathode catalyst (356.5 mW·cm⁻²) was higher than that using Ag/AC (329.3 mW·cm⁻²) and Ag/CB (256.6 mW·cm⁻²). The better cell performance obtained using a MWCNT support can be ascribed to the higher electrical conductivity and the larger electrochemical active surface area calculated from cyclic voltammetry measurements.     

Comparison of the Diamond-Forrester method and Duke Clinical Score to predict obstructive coronary artery disease by computed tomographic angiography

We sought to evaluate the ability of the Diamond and Forrester method (DFM) and the Duke Clinical Score (DCS) to predict obstructive coronary artery disease (CAD) on coronary computed tomographic angiography (CCTA) and the effect of these different risk scores on the appropriateness level using the 2010 Appropriate Use Criteria. Consecutive symptomatic patients who underwent CCTA for evaluation of CAD (n = 114) were classified as having a low, intermediate, or high pretest probability using the DFM and DCS. Using the Appropriate Use Criteria, the indications for CCTA were classified according to the pretest probability and previous testing. The CCTA results were classified as revealing obstructive (≥70% stenosis), nonobstructive (<70%), or no CAD. When the patients' risk was classified using the DFM, 18% were low, 65% intermediate, and 17% high risk. When using the DCS, 53% of patients had a reclassification of their risk, most of whom changed from intermediate to either low or high risk (50% low, 19% intermediate, 35% high risk). The net reclassification improvement for the prediction of obstructive CAD was 51% (p = 0.01). Of the 37 patients who were reclassified as low risk, 36 (97%) lacked obstructive CAD. Appropriateness for CCTA was reclassified for 13% of patients when using the DCS instead of the DFM, and the number of appropriate examinations was significantly fewer (68% vs 55%, p <0.001). In conclusion, reclassification of risk using the DCS instead of the DFM resulted in improved prediction of obstructive CAD on CCTA, especially in low-risk patients. More patients were categorized as having a high pretest probability of CAD, resulting in reclassification of their examination indications as uncertain or inappropriate. These results identify the need for improved pretest risk scores for noninvasive tests such as CCTA and suggest that the method of risk assessment could have important implications for patient selection and quality assurance programs.